Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
about
Different ovarian stimulation protocols for women with diminished ovarian reserveThe role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysisGnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.Evidence of GnRH antagonist escape in obese women.LH-RH analogues: I. Their impact on reproductive medicine.Predictive factors for recovery time in patients suffering from severe OHSS.Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamideEmbryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists.The Impact of Pituitary Blockage with GnRH Antagonist and Gonadotrophin Stimulation Length on The Outcome of ICSI Cycles in Women Older than 36 YearsComparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.Pharmaceutical options for triggering of final oocyte maturation in ARTLuteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH.Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.The correlation between follicular fluid pregnancy-associated plasma protein A levels, fertilization, and embryo quality in GnRH agonist and GnRH antagonist protocols in ART cycles.Cumulus cells gene expression profiling in terms of oocyte maturity in controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist.Cessation of gonadotropin-releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocolCetrorelix suppresses the preovulatory LH surge and ovulation induced by ovulation-inducing factor (OIF) present in llama seminal plasma.Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis.Effect of GnRH antagonists on clinical pregnancy rates in ovulation induction protocols with gonadotropins and intrauterine inseminationA Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists.Management of the poor responder: the role of GnRH agonists and antagonistsComparison of clinical outcome and costs with CC + gonadotropins and gnrha + gonadotropins during Ivf/ICSI cycles.Effect of in vivo GnRH agonist and GnRH antagonist on hCG and insulin-stimulated progesterone production by human granulosa-lutein cells in vitro.Clinical efficiency of Piezo-ICSI using micropipettes with a wall thickness of 0.625 μmIs a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?Affordable ART for developing countries: a cost benefit comparison of low dose stimulation versus high dose GnRH antagonist protocol.Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study.The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in in vitro fertilization-embryo transfer cycles.Gonadotrophin releasing hormone antagonist in IVF/ICSI.Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cyclesMicrodose GnRH Agonist Flare-Up versus Ultrashort GnRH Agonist Combined with Fixed GnRH Antagonist in Poor Responders of Assisted Reproductive Techniques Cycles.GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.Comparison of the ultrashort gonadotropin-releasing hormone agonist-antagonist protocol with microdose flare -up protocol in poor responders: a preliminary study.Is there a Need for Luteinizing Hormone (LH) Estimation in Patients Undergoing Ovarian Stimulation with Gonadotropin-Releasing Hormone (GnRH) Antagonists and Recombinant Follicle-Stimulating Hormone (rFSH)?The high responder: a review of pathophysiology and outcomes during IVF treatment.Embryo density may affect embryo quality during in vitro culture in a microwell group culture dish.Overview of elagolix for the treatment of endometriosis.
P2860
Q24634342-0BBD3DB3-7FA4-47A1-A1B5-ADDE670FBDD5Q24816913-F295E9BB-8E62-4FCD-9053-AB249E18154EQ28070299-DDC6F06F-CDD6-4843-85AE-2AC5AB3CD217Q33226124-EB8B9BFF-0D80-43D3-A441-A941C2E1277DQ33569055-DCC39F74-4EB2-45FD-9980-5AB095A21039Q33843858-4F20B065-5402-431D-883C-946B0539F1FAQ33896594-DD33B2FB-7AF2-4762-BC50-60A930CA3EB0Q33912179-C7798C58-3E59-4D10-BE0A-28F0A64A70E0Q33930196-806BB925-E8F2-4195-B0B7-323ADD8F7C99Q33937249-D8FEFB91-DD7B-421B-9EBD-7D6A52D294C2Q33947108-5555EBF7-3389-438F-BA16-DF76A2B767A9Q34009789-72D0120F-E2A2-4BCC-A9A1-5EA683BC26F5Q34106692-6D19CA63-8D69-45B7-838D-8425C3E535C0Q34201717-E13455F5-1DD1-49AA-B713-795D3384F7CAQ34216481-EE008E0F-428F-4BF4-B9B2-35788B3936E1Q34451981-F5549C02-60DF-46DC-BB95-8C7EED53F157Q34607007-A20493F1-ED84-42FF-BD10-F504145F9C16Q34629633-CCC06D77-F9DC-4DC5-AFCA-5C22A2062DB6Q34631083-50D4FF73-2221-4D19-8ADD-653310EE6D5FQ35749543-6EF3F440-E4BF-4358-95B5-734D763E3419Q35995836-47C90EF4-A33E-4D1B-AD02-4846D68938C4Q36235804-54877866-AA57-4BDF-96EF-AABFA2329AF7Q36249876-0C9EFB7C-58B7-4563-8C06-A3AE90BFBA1CQ36268626-A720CDC8-8028-462F-8A6B-61E3E2BF2C1CQ36269590-352F1287-BAE6-4133-A752-30B96315F383Q36271008-FB6A88CC-1169-4CAF-93A0-E580C753E8B5Q36378495-14E876D1-5C4F-4688-9A09-2047B6564777Q36423212-3E410DBB-243D-4A4D-917A-E1DF66A2E568Q37000769-DF9F8EDB-8049-4C40-B875-EC8FB53C4C02Q37022407-691BCCD4-B321-48A5-8DE3-8B44FFBE15A5Q37022412-3B816388-D2F5-41F6-910E-514065A4CBB7Q37238190-9BEB89D2-8F45-48AA-BE32-73A1FFE74386Q37350469-77247147-C3F8-44FB-B1DE-62DCA4781735Q37362849-E46217F7-EA17-4A13-A889-9AE20E4DBCB3Q37598922-B2975FDB-CBAC-49C9-8CEE-A43BCCE96E06Q37611176-A8EA9C34-1C2C-4BF1-AEC8-589381E4A976Q37612044-8EC86086-0CFA-4A39-9DD9-3E1F942C3860Q38716011-5174E27F-194E-4AD3-8C48-0A26836BCE66Q38759836-22ED4F45-1338-4627-AE07-94658D02F744Q38791644-A3C5D145-C98A-4DE9-A1B4-B7BFADE45342
P2860
Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Suppression of the endogenous ...... ix during ovarian stimulation.
@en
Suppression of the endogenous ...... ix during ovarian stimulation.
@nl
type
label
Suppression of the endogenous ...... ix during ovarian stimulation.
@en
Suppression of the endogenous ...... ix during ovarian stimulation.
@nl
prefLabel
Suppression of the endogenous ...... ix during ovarian stimulation.
@en
Suppression of the endogenous ...... ix during ovarian stimulation.
@nl
P2093
P1433
P1476
Suppression of the endogenous ...... ix during ovarian stimulation.
@en
P2093
C Diedrich
D Klingmüller
K Diedrich
S al-Hasani
T Reissmann
P304
P356
10.1093/OXFORDJOURNALS.HUMREP.A138597
P407
P577
1994-05-01T00:00:00Z